Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab

[1]  C. Coopersmith,et al.  Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)* , 2019, Critical care medicine.

[2]  K. Savage,et al.  Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  F. Venet,et al.  Advances in the understanding and treatment of sepsis-induced immunosuppression , 2018, Nature Reviews Nephrology.

[4]  C. Meisel,et al.  Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers , 2017, Intensive Care Medicine Experimental.

[5]  Susan Gruber,et al.  Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014 , 2017, JAMA.

[6]  B. Brumback,et al.  Evidence for Persistent Immune Suppression in Patients Who Develop Chronic Critical Illness After Sepsis , 2017, Shock.

[7]  F. Swirski,et al.  Cytokine storm and sepsis disease pathogenesis , 2017, Seminars in Immunopathology.

[8]  D. Maucort-Boulch,et al.  Association between mRNA expression of CD74 and IL10 and risk of ICU-acquired infections: a multicenter cohort study , 2017, Intensive Care Medicine.

[9]  Sangeeta Mehta,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 , 2017, Intensive Care Medicine.

[10]  R. Bellomo,et al.  Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit , 2017, JAMA.

[11]  R. Hotchkiss,et al.  Frontline Science: Defects in immune function in patients with sepsis are associated with PD‐1 or PD‐L1 expression and can be restored by antibodies targeting PD‐1 or PD‐L1 , 2016, Journal of leukocyte biology.

[12]  K. Brohi,et al.  Persistent lymphopenia is an independent predictor of mortality in critically ill emergency general surgical patients , 2016, European Journal of Trauma and Emergency Surgery.

[13]  J. Knight,et al.  Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study , 2016, The Lancet. Respiratory medicine.

[14]  D. Angus,et al.  Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. , 2016, American journal of respiratory and critical care medicine.

[15]  J. Chiche,et al.  Timing and causes of death in septic shock , 2015, Annals of Intensive Care.

[16]  Jia-feng Wang,et al.  Up-regulation of Programmed Cell Death 1 Ligand 1 on Neutrophils May Be Involved in Sepsis-induced Immunosuppression: An Animal Study and a Prospective Case-control Study , 2015, Anesthesiology.

[17]  R. Hotchkiss,et al.  Persistent Lymphopenia After Diagnosis of Sepsis Predicts Mortality , 2014, Shock.

[18]  G. Escobar,et al.  Hospital deaths in patients with sepsis from 2 independent cohorts. , 2014, JAMA.

[19]  J. Marshall.  Why have clinical trials in sepsis failed? , 2014, Trends in molecular medicine.

[20]  R. Hotchkiss,et al.  Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis , 2014, Critical Care.

[21]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[22]  R. Hotchkiss,et al.  Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis , 2013, Critical Care.

[23]  T. Chiba,et al.  Reduction of Immunocompetent T Cells Followed by Prolonged Lymphopenia in Severe Sepsis in the Elderly* , 2013, Critical care medicine.

[24]  James J. Yang,et al.  Early Biomarker Activity in Severe Sepsis and Septic Shock and a Contemporary Review of Immunotherapy Trials: Not a Time to Give Up, But to Give It Earlier , 2013, Shock.

[25]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 , 2013, Critical care medicine.

[26]  Michael G. Katze,et al.  Into the Eye of the Cytokine Storm , 2012, Microbiology and Molecular Reviews.

[27]  J. Machan,et al.  Failure to normalize lymphopenia following trauma is associated with increased mortality, independent of the leukocytosis pattern , 2012, Critical Care.

[28]  R. Hotchkiss,et al.  Immunosuppression in patients who die of sepsis and multiple organ failure. , 2011, JAMA.

[29]  B. Allaouchiche,et al.  Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients , 2011, Critical care.

[30]  Yan Zhang,et al.  Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients , 2011, Critical care.

[31]  Yan Zhang,et al.  PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction , 2010, Critical care.

[32]  R. Hotchkiss,et al.  Delayed administration of anti‐PD‐1 antibody reverses immune dysfunction and improves survival during sepsis , 2010, Journal of leukocyte biology.

[33]  C. Chung,et al.  PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis , 2009, Proceedings of the National Academy of Sciences.

[34]  N. Voirin,et al.  Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock , 2006, Intensive Care Medicine.

[35]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[36]  R. Hotchkiss,et al.  Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans1 , 2001, The Journal of Immunology.

[37]  E. Abraham,et al.  Why immunomodulatory therapies have not worked in sepsis , 1999, Intensive Care Medicine.

[38]  S. Mackinnon,et al.  Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. , 1999, Blood.

[39]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[40]  J. Vincent,et al.  Novel Interventions: What's New and the Future. , 2018, Critical care clinics.

[41]  R. Hotchkiss,et al.  Nivolumab plus interferon-γ in the treatment of intractable mucormycosis. , 2017, The Lancet. Infectious diseases.

[42]  J. Timsit,et al.  Inter‐laboratory assessment of flow cytometric monocyte HLA‐DR expression in clinical samples , 2013, Cytometry. Part B, Clinical cytometry.

[43]  S. Mackinnon,et al.  Comparison of Immune Reconstitution After Unrelated and Related T-Cell – Depleted Bone Marrow Transplantation : Effect of Patient Age and Donor Leukocyte Infusions , 1998 .